Methods for treating Angelman syndrome and related disorders
Provided herein are methods of treating Angelman Syndrome and/or Prader-Willi syndrome, that include administering an effective amount of a T-type calcium channel antagonist to a subject in need of the treatment.
1. A method of reducing or ameliorating seizure associated with Angelman Syndrome, said method comprising administering to a subject in need thereof a therapeutically effective amount of a T-type calcium channel antagonist, wherein the T-type calcium channel antagonist is MK-8998:
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein said T-type calcium channel antagonist is MK-8998:
3. The method of claim 1 , further comprising administering to the subject an additional therapeutic agent.
4. The method of claim 3 , wherein the additional therapeutic agent is an additional T-type calcium channel inhibitor.
5. The method of claim 3 , wherein the additional therapeutic agent is an anticonvulsive agent.
6. The method of claim 1 , further comprising administering an additional therapy selected from the group consisting of physical therapy, occupational therapy, communication therapy, and behavioral therapy.
7. The method of claim 1 , wherein the reducing or ameliorating seizure associated with Angelman Syndrome comprises reducing the frequency of seizure in the subject in need thereof.
8. The method of claim 1 , wherein the reducing or ameliorating seizure associated with Angelman Syndrome comprises reducing the severity of seizure in the subject in need thereof.
9. The method of claim 1 , wherein the reducing or ameliorating seizure associated with Angelman Syndrome comprises reducing the frequency and severity of seizure in the subject in need thereof.